4.6 Article

Reversion of gene expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells

Journal

CELL CYCLE
Volume 10, Issue 9, Pages 1448-1455

Publisher

TAYLOR & FRANCIS INC
DOI: 10.4161/cc.10.9.15487

Keywords

Chagas disease; Trypanosoma cruzi; cardiomyopathy; cell transplantation; microarray; inflammation; fibrosis

Categories

Funding

  1. National Institutes of Health [HL-73732, HD-32573, AI-076248]
  2. CAPES
  3. CNPq
  4. FINEP
  5. FAPERJ
  6. FAPESB
  7. Fogarty International Training Grant [D43TW007129]

Ask authors/readers for more resources

Chronic chagasic cardiomyopathy is a leading cause of heart failure in Latin American countries, being associated with intense inflammatory response and fibrosis. We have previously shown that bone marrow mononuclear cell (BMC) transplantation improves inflammation, fibrosis and ventricular diameter in hearts of mice with chronic Chagas disease. Here we investigated the transcriptomic recovery induced by BMC therapy by comparing the heart transcriptomes of chagasic mice treated with BMC or saline with control animals. Out of the 9,390 unique genes quantified in all samples, 1,702 had their expression altered in chronic chagasic hearts compared to those of normal mice. Major categories of significantly upregulated genes were related to inflammation, fibrosis and immune responses, while genes involved in mitochondrion function were downregulated. When BMC-treated chagasic hearts were compared to infected mice, 96% of the alterations detected in infected hearts were restored to normal levels, although an additional 109 genes were altered by treatment. Transcriptomic recovery, a new measure that considers both restorative and side effects of treatment, was remarkably high (84%). Immunofluorescence and morphometric analyses confirmed the effects of BMC therapy in the pattern of inflammatory-immune response and expression of adhesion molecules. In conclusion, by using large-scale gene profiling for unbiased assessment of therapeutic efficacy we demonstrate immunomodulatory effects of BMC therapy in chronic chagasic cardiomyopathy and identify potentially relevant factors involved in the pathogenesis of the disease that may provide new therapeutic targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available